Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, ...

Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which included $375 million in cash ...

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Read more here.

A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...

Tempus announced its acquisition of Ambry Genetics for $375 million in cash and $225 million in shares at closing in November and the deal closed earlier this month. Ambry will continue to operate ...

The company recently completed its acquisition of Ambry Genetics, providing Tempus AI with the ability to offer patients more comprehensive cancer screening with Ambry's hereditary cancer assay.

The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics ("Ambry"), which closed on February 3, 2025. Combined with $260 million of capital provided in ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...

All on news it just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which included $375 million in cash payments and $225 million in shares. Plus, Nancy Pelosi ...